



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

December 31, 2019

Ronald Kempers  
President and Chief Executive Officer  
Mymetics Corporation  
Route de la Corniche 4  
1066 Epalinges, Switzerland

**Re: Mymetics Corporation**  
**Preliminary Information Statement on Schedule 14C**  
**Filed December 27, 2019**  
**File No. 000-25132**

Dear Mr. Kempers:

We have reviewed your filing and have the following comment.

Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to the comment, we may have additional comments.

Preliminary Information Statement on Schedule 14C

General

1. Please revise your disclosure to describe any current plans, arrangements or understandings relating to the issuance of any of the newly authorized shares that would be available as a result of the proposed increase in authorized shares, including the terms of any current financing plans. If you have no such plans, arrangements or understandings, please revise your disclosure to so state.

We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Ronald Kempers  
Mymetics Corporation  
December 31, 2019  
Page 2

Please contact Chris Edwards at (202) 551-6761 or Mary Beth Breslin at (202) 551-3625 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Ernest M. Stern